Show simple item record

dc.contributor.authorPopovici, J.
dc.contributor.authorVantaux, A.
dc.contributor.authorPrimault, L.
dc.date.accessioned2019-06-05T18:28:20Z
dc.date.available2019-06-05T18:28:20Z
dc.date.issued2018
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85050398698&doi=10.3201%2feid2408.170768&partnerID=40&md5=5446b825781354cdb60ad5902847f51a
dc.identifier.urihttp://hdl.handle.net/10713/9468
dc.description.abstractWe assessed the efficacy of standard 3-day courses of chloroquine and dihydroartemisinin/piperaquine against Plasmodium vivax malaria. Compared with chloroquine, dihydroartemisinin/piperaquine was faster in clearing asexual P. vivax parasites and blocking human-to-mosquito transmission. This drug combination was also more effective in preventing potential recurrences for >2 months. Copyright 2018, Centers for Disease Control and Prevention (CDC). All rights reserved.en_US
dc.description.sponsorshipThis study was supported by the National Institute of Allergy and Infectious Diseases, National Institutes of Health (grant R01 434 A103328) and the Institut Pasteur (grant PTR 2014-490). A.V. was supported by a Calmette and Yersin fellowship from the Institut Pasteur International Network.en_US
dc.description.urihttps://dx.doi.org/10.3201/eid2408.170768en_US
dc.language.isoen-USen_US
dc.publisherCenters for Disease Control and Prevention (CDC)en_US
dc.relation.ispartofEmerging Infectious Diseases
dc.subjectdihydroartemisinin/piperaquineen_US
dc.subject.meshChloroquineen_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshMalaria, Vivax--prevention & controlen_US
dc.titleTherapeutic and transmission-blocking efficacy of dihydroartemisinin/ piperaquine and chloroquine against Plasmodium vivax Malaria, Cambodiaen_US
dc.typeArticleen_US
dc.identifier.doi10.3201/eid2408.170768
dc.identifier.pmid29798745


This item appears in the following Collection(s)

Show simple item record